Physician profile
Tresa Chakkalakkal
NPI 1053535906
$1,154.46
in general payments reported to CMS, 2019-2025
14 companies · $283 in 2025
The $283 reported for 2025 was more than what 83% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $64.74 · 2020: $63.74 · 2021: $139 · 2022: $173 · 2023: $288 · 2024: $143 · 2025: $283.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $714.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $713.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $535.40 | 2021-2025 | Gardasil 9, Vaxneuvance, Rotateq |
| Glaxosmithkline, LLC. | $153.65 | 2020-2024 | Bexsero |
| Pfizer INC. | $74.36 | 2019-2024 | |
| Kaleo, INC. | $71.21 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $63.83 | 2021-2023 | |
| Kowa Pharmaceuticals America, INC. | $45.96 | 2025 | Zoryve |
| Supernus Pharmaceuticals, INC. | $42.10 | 2022 | |
| Neos Therapeutics, Lp | $39.31 | 2019-2020 | |
| Genzyme Corporation | $32.82 | 2025 | |
| Ucb, INC. | $25.46 | 2022 | |
| Verrica Pharmaceuticals INC. | $22.39 | 2025 | Ycanth |
| Sanofi Pasteur INC. | $17.20 | 2023 | |
| Boston Scientific Corporation | $16.54 | 2022 | |
| Seqirus USA INC | $14.23 | 2025 | Flucelvax |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tresa Chakkalakkal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.